197 related articles for article (PubMed ID: 31398418)
1. The dipeptidyl peptidase 4 inhibitor sitagliptin improves oxidative stress and ameliorates glomerular lesions in a rat model of type 1 diabetes.
Marques C; Gonçalves A; Pereira PMR; Almeida D; Martins B; Fontes-Ribeiro C; Reis F; Fernandes R
Life Sci; 2019 Oct; 234():116738. PubMed ID: 31398418
[TBL] [Abstract][Full Text] [Related]
2. Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes.
Kodera R; Shikata K; Takatsuka T; Oda K; Miyamoto S; Kajitani N; Hirota D; Ono T; Usui HK; Makino H
Biochem Biophys Res Commun; 2014 Jan; 443(3):828-33. PubMed ID: 24342619
[TBL] [Abstract][Full Text] [Related]
3. Dipeptidyl peptidase-IV inhibition prevents blood-retinal barrier breakdown, inflammation and neuronal cell death in the retina of type 1 diabetic rats.
Gonçalves A; Marques C; Leal E; Ribeiro CF; Reis F; Ambrósio AF; Fernandes R
Biochim Biophys Acta; 2014 Sep; 1842(9):1454-63. PubMed ID: 24769045
[TBL] [Abstract][Full Text] [Related]
4. Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat).
Mega C; de Lemos ET; Vala H; Fernandes R; Oliveira J; Mascarenhas-Melo F; Teixeira F; Reis F
Exp Diabetes Res; 2011; 2011():162092. PubMed ID: 22203828
[TBL] [Abstract][Full Text] [Related]
5. The dipeptidyl peptidase-4 inhibitor sitagliptin ameliorates renal injury in type 1 diabetic mice
Li L; Lian X; Wang Z; Zheng J; Liu J; Chu Y; Teng Y; Zhang Z
Pharmazie; 2019 Apr; 74(4):239-242. PubMed ID: 30940309
[TBL] [Abstract][Full Text] [Related]
6. Influence of Dipeptidyl Peptidase-IV Inhibitor Sitagliptin on Extracellular Signal-Regulated Kinases 1/2 Signaling in Rats with Diabetic Nephropathy.
Ren X; Liu G; Wang Y; Zhang W; Xue F; Li R; Yu W
Pharmacology; 2017; 100(1-2):1-13. PubMed ID: 28329747
[TBL] [Abstract][Full Text] [Related]
7. Effect of concomitant administration of coenzyme Q10 with sitagliptin on experimentally induced diabetic nephropathy in rats.
Maheshwari R; Balaraman R; Sen AK; Shukla D; Seth A
Ren Fail; 2017 Nov; 39(1):130-139. PubMed ID: 27841100
[TBL] [Abstract][Full Text] [Related]
8. Effect of sitagliptin on tubulointerstitial Wnt/β-catenin signalling in diabetic nephropathy.
Ren X; Zhu R; Liu G; Xue F; Wang Y; Xu J; Zhang W; Yu W; Li R
Nephrology (Carlton); 2019 Nov; 24(11):1189-1197. PubMed ID: 31412145
[TBL] [Abstract][Full Text] [Related]
9. Modulating impacts of quercetin/sitagliptin combination on streptozotocin-induced diabetes mellitus in rats.
Eitah HE; Maklad YA; Abdelkader NF; Gamal El Din AA; Badawi MA; Kenawy SA
Toxicol Appl Pharmacol; 2019 Feb; 365():30-40. PubMed ID: 30576699
[TBL] [Abstract][Full Text] [Related]
10. Sitagliptin alleviated myocardial remodeling of the left ventricle and improved cardiac diastolic dysfunction in diabetic rats.
Liu YS; Huang ZW; Wang L; Liu XX; Wang YM; Zhang Y; Zhang M
J Pharmacol Sci; 2015 Mar; 127(3):260-74. PubMed ID: 25837922
[TBL] [Abstract][Full Text] [Related]
11. Effect of siglidine on glucose lipid metabolism and the expression of iNOS and GLP-1 receptors in diabetic rats.
Zhang HY; Li Y; Zhong YH; Ruan LB; Yang TR; Yin HP
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8984-8989. PubMed ID: 30575943
[TBL] [Abstract][Full Text] [Related]
12. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, improves recognition memory, oxidative stress and hippocampal neurogenesis and upregulates key genes involved in cognitive decline.
Gault VA; Lennox R; Flatt PR
Diabetes Obes Metab; 2015 Apr; 17(4):403-13. PubMed ID: 25580570
[TBL] [Abstract][Full Text] [Related]
13. Critical role of renal dipeptidyl peptidase-4 in ameliorating kidney injury induced by saxagliptin in Dahl salt-sensitive hypertensive rats.
Sakai M; Uchii M; Myojo K; Kitayama T; Kunori S
Eur J Pharmacol; 2015 Aug; 761():109-15. PubMed ID: 25936515
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical, apoptotic and biochemical changes by dipeptidyl peptidase-4 inhibitor-sitagliptin in type-2 diabetic rats.
Karabulut S; Coskun ZM; Bolkent S
Pharmacol Rep; 2015 Oct; 67(5):846-53. PubMed ID: 26398375
[TBL] [Abstract][Full Text] [Related]
15. DPP IV inhibitor treatment attenuates bone loss and improves mechanical bone strength in male diabetic rats.
Glorie L; Behets GJ; Baerts L; De Meester I; D'Haese PC; Verhulst A
Am J Physiol Endocrinol Metab; 2014 Sep; 307(5):E447-55. PubMed ID: 25053403
[TBL] [Abstract][Full Text] [Related]
16. CB-1R and GLP-1R gene expressions and oxidative stress in the liver of diabetic rats treated with sitagliptin.
Coskun ZM; Koyuturk M; Karabulut S; Bolkent S
Pharmacol Rep; 2017 Aug; 69(4):822-829. PubMed ID: 28599244
[TBL] [Abstract][Full Text] [Related]
17. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, attenuates apoptosis of vascular smooth muscle cells and reduces atherosclerosis in diabetic apolipoprotein E-deficient mice.
Li B; Luo YR; Zhang Q; Fu SH; Chen YD; Tian JW; Guo Y
Vascul Pharmacol; 2021 Oct; 140():106854. PubMed ID: 33781961
[TBL] [Abstract][Full Text] [Related]
18. Sitagliptin Mitigates Diabetic Nephropathy in a Rat Model of Streptozotocin-Induced Type 2 Diabetes: Possible Role of PTP1B/JAK-STAT Pathway.
Al-Qabbaa SM; Qaboli SI; Alshammari TK; Alamin MA; Alrajeh HM; Almuthnabi LA; Alotaibi RR; Alonazi AS; Bin Dayel AF; Alrasheed NM; Alrasheed NM
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047505
[TBL] [Abstract][Full Text] [Related]
19. Anti-Inflammatory Action of Sitagliptin and Linagliptin in Doxorubicin Nephropathy.
Jo CH; Kim S; Park JS; Kim GH
Kidney Blood Press Res; 2018; 43(3):987-999. PubMed ID: 29913457
[TBL] [Abstract][Full Text] [Related]
20. Sitagliptin attenuates cardiomyopathy by modulating the JAK/STAT signaling pathway in experimental diabetic rats.
Al-Rasheed NM; Al-Rasheed NM; Hasan IH; Al-Amin MA; Al-Ajmi HN; Mahmoud AM
Drug Des Devel Ther; 2016; 10():2095-107. PubMed ID: 27418808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
